NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial
NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial
FT. WORTH, (March 9, 2021) — NanOlogy, LLC, a clinical-stage oncology company, today announced that enrollment has been completed in its clinical trial of NanoDoce® for bladder cancer.
Local bladder cancer at high risk for progression often requires removal of the bladder resulting in a severe lifelong quality of life issues. NanOlogy enrolled 36 bladder cancer patients in a Phase 1/2 two-arm trial evaluating direct injection/instillation of NanoDoce® Suspension.
The first arm (n=19) included patients with high risk nonmuscle invasive bladder cancer. A high majority to date had a complete response at 3 months with 12 month data available in 2Q2021.
The second arm (n=17) included patients with muscle invasive bladder cancer. More than half have retained their bladder with no intervention at the initial study endpoint, now extended up to 12 months to test durability. These preliminary results will be updated and published once final.
###
About NanOlogy
NanOlogy, LLC (www.nanology.us) is a private clinical stage oncology company formed in 2015 to finance and clinically advance tumor-directed drug therapy for solid tumors based on a proprietary supercritical precipitation technology platform.
Disclaimers
This announcement contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including statements about our product development, business, and other activities. Such statements are subject to the risks and uncertainties inherent in any pharmaceutical development program which may cause actual results to differ materially due to developmental, clinical trial, regulatory, market, competitive, technological, or other factors. All forward-looking statements are made as of the date of this announcement and the company disclaims any intent or obligation to update these statements. NanOlogy investigational drugs have not been proven to be safe and effective as required by U.S. FDA and have not been approved by FDA or any other regulatory authority for commercial distribution. NanOlogy, NanoDoce, and NanoPac are trademarks of NanOlogy LLC.
Media Contact
Dan Eramian
Opus Biotech Communications
danieleramian@comcast.net
425-306-8716
Charles Craig
Opus Biotech Communications
charles.s.craig@gmail.com
404-245-0591